SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp futures rebound after Fridays selloff has turned the discussion from Black Monday crash warnings to whether the market can sustain the bounce. Traders debate whether it reflects genuine dip-buying or a fragile overnight short-covering move, with some linking optimism to possible Russia-Ukraine developments and easing oil prices while others expect a reversal.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The prolonged wait for SELLASs REGAL Phase 3 trial to reach its 80th death eventand the subsequent final analysisdominates discussion; the last disclosed count was 78, and the company has not confirmed the trigger. Bulls interpret the delay and quiet period as a possible sign of longer survival and speculate about an ASH data reveal, while skeptics see uncertainty around the trial and disclosure timeline; the stocks sharp decline has intensified that debate.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp tech- and AI-led selloff has put QQQ under pressure, while a strong rebound in futures prompted traders to debate whether the bounce can hold or is a bull trap. Black Monday anniversary crash warnings amplified the volatility, but many traders dismissed them as the rebound gathered momentum.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are under pressure amid IPO lockup expirations that make additional insider and employee shares eligible for sale, compounded by a broader AI and semiconductor selloff. Traders disagree on whether the added supply and concerns about valuation, scalability, and customer concentration will prolong the decline or whether the selloff is overdone given Cerebras inference technology.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention after a sharp semiconductor selloff, with its 3 leverage magnifying losses and the subsequent rebound. Traders are split between buying an oversold bounce and expecting more downside amid concerns about AI spending and debt, Chinese competition, and persistent inflation.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a broad neocloud and AI-infrastructure selloff as investors question the sectors debt-fueled expansion, financing costs, and path to returns. Traders are split between viewing the decline as an overdone pullbackoften arguing Nebius is better positioned than some peersand expecting further downside amid sector-wide risk concerns.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is drawing attention after a sharp price and volume rally, with traders watching for a sustained technical breakout. Bullish holders point to the Flexa/Anvil payments and collateral thesis, while skeptics argue the move may be another short-lived pump; no confirmed new catalyst dominates the discussion.

Direxion Shares ETF Trust - Direxion Daily MU Bull 2X ETF

Direxion Daily MU Bull 2X Shares

MUU is drawing attention amid a sharp pullback in Micron and memory stocks, with traders debating whether sector selling and concerns about AI demand signal further downside or a buying opportunity. Some are adding for a rebound, while others warn that MUUs 2x leverage can amplify losses and volatility decay during choppy trading.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

ESMO updates on Iovances lifileucel program are driving attention, especially mature frontline melanoma data for lifileucel plus pembrolizumab that traders view as showing durable activity. The reaction is mixed: some see the results as supportive of the ongoing Phase 3 trial, while others argue the small cohort and largely consistent readout limit how much is new; early sarcoma results are also being watched cautiously pending larger-trial validation.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

A strong quarterly report and upbeat cloud outlook drove a sharp rally, with traders also discussing Atlassians AI products as evidence that enterprise software can benefit from rather than be displaced by AI. Some see cloud demand and improving execution supporting the recovery, while others warn the run-up is overextended and point to valuation and AI-related seat-compression risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

High-Stakes Corporate Stories Putting Strategic Moves in the Spotlight

Today's corporate developments highlight some very different investment narratives: NeOnc Technologies Holdings (NASDAQ:NTHI) is pursuing new avenues for experimental brain-cancer treatments, Alector (NASDAQ:ALEC) is raising fresh capital for neurological disease research, Alaunos Therapeutics (NASDAQ:TCRT) is repositioning around pulmonary hypertension through a major acquisition, Zenta Group (NASDAQ:ZTG) is pursuing an artificial intelligence and data-services strategy, and Exascale Labs (NASDAQ:XLAB) is seeking to convert surging AI-computing demand into commercial growth.

NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi

Others

NeOnc’s Boldest Test Yet: Child’s Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone

NeOnc Technologies Holdings (NASDAQ:NTHI) delivered a deeply human clinical update that brings its investigational brain-cancer technology, expanding Abu Dhabi presence and high-profile banking appointment into sharper focus. The company reported that a critically ill three-year-old boy with an aggressive brain tumor is breathing independently without ventilator support and beginning to move his legs after receiving investigational intranasal NEO100 through NeOnc’s Compassionate Care program. The treatment is being administered outside the company’s pediatric clinical trial, following coordination with the child’s physicians and the Department of Health – Abu Dhabi. While a single compassionate-use case cannot establish that NEO100 caused the reported improvement, the decision to make an investigational treatment available to a critically ill child underscores the importance of the technology to NeOnc’s development strategy and raises the stakes for the company to demonstrate its potential through rigorous clinical research.

Companies Entering High-Stakes Market Moments

The following developments are worth watching, with Dermata Therapeutics (NASDAQ:DRMA), Verastem (NASDAQ:VSTM), NeOnc Technologies Holdings (NASDAQ:NTHI), Netcapital (NASDAQ:NCPL), Iambic Therapeutics (NASDAQ:IAM) and Estrella Immunopharma (NASDAQ:ESLA) advancing distinct strategies.

NeOnc CEO Amir F. Heshmatpour to Address Global Life Sciences Investment at Abu Dhabi Future Health Summit 2026

From Shaq to Musk: The Power of a High-Profile Appointment

The right appointment can do far more than fill a board seat. It can elevate a company’s public profile, open doors to strategic partnerships, influence commercial direction and reshape how investors view its growth potential. $NTHI, $PZZA, $TSLA,  $SPCX, $UMAC

UAE Banking Powerhouse Joins NeOnc as Brain-Cancer Drug Pipeline Advances

NeOnc Technologies Holdings (NASDAQ:NTHI) is strengthening its boardroom at a pivotal moment in its brain-cancer drug development strategy, appointing Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank (FAB), to its Board of Directors.

Wall Street’s Next Movers

The market is serving up a powerful mix of movers, including Alaunos Therapeutics (NASDAQ:TCRT) completed a major acquisition backed by a $350 million private placement, while NeOnc Technologies Holdings (NASDAQ:NTHI) is preparing for an important FDA discussion. Verastem Oncology (NASDAQ:VSTM) reported fresh cancer-drug results alongside a major financing and leadership transition, and Liquidia (NASDAQ:LQDA) resolved a prolonged legal battle over its pulmonary-hypertension treatment. Bending Spoons (NASDAQ:BSP) is attracting another major investment from Berkshire Hathaway.

NeOnc Technologies Appoints Ali Alabedin to Its Board of Directors

NeOnc Bolsters Boardroom Leadership as Abu Dhabi Expansion Advances Brain Cancer Drug Development

NeOnc Technologies Holdings (NASDAQ:NTHI) is strengthening its leadership as it advances clinical development of therapies targeting some of the most challenging cancers to treat. The clinical-stage biopharmaceutical company appointed Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, to its Board of Directors, effective October 9, 2026. With more than three decades of international banking and executive leadership experience, Alabedin brings financial governance and global business expertise as NeOnc pursues clinical-development opportunities in Abu Dhabi and advances its brain cancer drug pipeline.

This account has been verified as an official NTHI representative.

Verified Account

NeOnc Technologies

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.

NeOnc Technologies Holdings Inc.

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$2.70
Prev Close	$2.75
Open	$2.80
Dividend Yield	0.00%
50-Day Moving Average	$3.72
Beta	0.00
Avg. Volume	202,273.82
PE Ratio	-1.27

52-Week High	$12.00
52-Week Low	$2.50
Market Capitalization	$77.77M
EPS (Annual)	-$2.87
Price to Book	-3.62
Revenue Per Employee	$7,998.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

NTHI Fundamentals